Literature DB >> 25591671

Epilepsy: some controversies, some knowledge and some experience from Cambodia.

Chamroeun Hun, Tola Hok, Sina Ros, Samleng Chan, Devender Bhalla1.   

Abstract

Epilepsy-related health outcomes remain unacceptably low in much of the developing world. According to us, it is because of the failure since long to see, and address, epilepsy beyond its preset conventional image. The objective of this paper was to highlight the presence, and influence, of these conventional practices and also to demonstrate what happened when a bold unconventional approach to address epilepsy was taken in Cambodia. Data are taken from existing published literature on epilepsy as well as our field experience during several population-based surveys conducted in Cambodia. We complimented this with our knowledge gained over this long period. It is demonstrated that epilepsy is far more important in Asia that it is currently considered to be, and also vis-à-vis other geographic regions. Pregnancy and birth-related factors carry far higher odds for epilepsy than several "highly vocal" infections. A refocus in epilepsy is required to help move from its traditional negative image to an image where epilepsy is considered a "positive-looking" disorder that is full of "opportunities;" such as availability of safe effective inexpensive treatment, etc. Stigma is a two-side entity (i.e., it is present, and it is influential), and diligence should be therefore practiced before using the stigma label. Nevertheless, psychosocial aspects shouldn't be limited to stigma or Jacoby stigma scale alone. Quality of life is a subjective phenomenon, and patients should determine directly what affects them. It is highly desirable that if we want to find newer answers to old problems in epilepsy, we need to shed our conventional approach and preset conclusions. We should choose to move toward "opportunities" visibly present in epilepsy. Our Cambodian experience demonstrates more intimately that opportunities do get identified when preset conclusions are questioned, and an approach that goes beyond expected and by default is taken.

Entities:  

Mesh:

Year:  2014        PMID: 25591671     DOI: 10.4103/0028-3886.149376

Source DB:  PubMed          Journal:  Neurol India        ISSN: 0028-3886            Impact factor:   2.117


  7 in total

1.  Evaluation of Fear in Idiopathic Epilepsy Using Population-Based Survey and Bhalla-Gharagozli Fear in Epilepsy Questionnaire (BG-FEQ).

Authors:  Kurosh Gharagozli; Elham Lotfalinezhad; Fatemeh Amini; Vida Saii; Devender Bhalla
Journal:  Neuropsychiatr Dis Treat       Date:  2020-07-10       Impact factor: 2.570

2.  Medication Beliefs and Adherence to Antiseizure Medications.

Authors:  Devender Bhalla; Elham Lotfalinezhad; Fatemeh Amini; Ahmad Delbari; Reza Fadaye-Vatan; Vida Saii; Kurosh Gharagozli
Journal:  Neurol Res Int       Date:  2020-10-23

3.  Knowledge and practice of schoolteachers towards students with epilepsy in Khamis Mushate, Southern Saudi Arabia.

Authors:  Jobran M Alqahtani
Journal:  J Family Community Med       Date:  2015 Sep-Dec

4.  Knowledge, Attitude, and Practice among Practitioners Regarding Epilepsy in Bhutan: A Rural and a Remote Country.

Authors:  Devender Bhalla
Journal:  J Neurosci Rural Pract       Date:  2017 Oct-Dec

5.  Availability and sufficiency of phenobarbital, an essential medication, in Bhutan: a survey of global and neuropsychiatric relevance.

Authors:  Devender Bhalla
Journal:  BMC Res Notes       Date:  2018-08-02

6.  Malaria Prevention Measures among Pregnant Women: A Population-Based Survey in Nnewi, Nigeria.

Authors:  Devender Bhalla; Laurent Cleenewerck; Stephen Okorafor Kalu; Kabiru Abubakar Gulma
Journal:  ScientificWorldJournal       Date:  2019-11-13

7.  Availability, affordability, and quality of essential anti-seizure medication in Cambodia.

Authors:  Noudy Sengxeu; Chanraksmey Aon; Hanh Dufat; Farid Boumediene; Samleng Chan; Sina Ros; Pierre-Marie Preux; Voa Ratsimbazafy; Jeremy Jost
Journal:  Epilepsia Open       Date:  2021-06-23
  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.